散发性和地方性伯基特淋巴瘤中FOXO1突变频繁但AKT识别基序热点不同
研究对大量儿童伯基特淋巴瘤(BL)样本进行测序,发现散发性和地方性BL中FOXO1突变频率分别为29%(23/78)和54%(48/89),复发样本为50%(8/16)。散发型以T24突变最常见,地方型以S22突变最常见;FOXO1突变几乎均存在于主要肿瘤克隆中,但与预后无关,且与DDX3X和ARID1A突变相关。
要点
- 散发性和地方性BL中FOXO1突变频率分别为29%和54%,复发样本为50%。
- 散发型BL以T24突变最常见,地方型BL以S22突变最常见。
- FOXO1突变与DDX3X和ARID1A突变相关,但与预后无关。
核心结论
- FOXO1在散发性和地方性BL中均频繁突变,可能为全球儿童BL患者的潜在治疗靶点。
研究设计与样本
- 对大量散发性和地方性BL患者样本进行FOXO1测序,包括诊断和复发样本。
主要发现
- FOXO1突变在散发性BL中为23/78(29%),地方性BL中为48/89(54%),复发样本中为8/16(50%)。
- 散发型BL中T24突变最常见,地方型BL中S22突变最常见。
- FOXO1突变几乎均存在于主要肿瘤细胞克隆中,但与预后无关。
- FOXO1突变与DDX3X和ARID1A突变相关,与MYC、TCF3/ID3或磷脂酰肌醇3-激酶信号通路成员突变无关。
- 无论突变状态如何,FOXO1蛋白常见核滞留;CRISPR/Cas9敲除地方性细胞系中FOXO1可显著降低细胞增殖。
临床怎么用
- FOXO1突变状态可能作为儿童BL的潜在治疗靶点,但需进一步研究验证。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
FOXO1 has an oncogenic role in adult germinal center-derived lymphomas, in which mutations, predominately within the AKT recognition motif, cause nuclear retention of FOXO1, resulting in increased cell proliferation. To determine the prevalence and distribution of FOXO1 mutations in pediatric Burkitt lymphoma (BL), we sequenced a large number of sporadic and endemic BL patient samples. We report a high frequency of FOXO1 mutations in both sporadic and endemic BL at diagnosis, occurring in 23/78 (29%) and 48/89 (54%) samples, respectively, as well as 8/16 (50%) cases at relapse. Mutations of T24 were the most common in sporadic BL but were rare in endemic cases, in which mutations of residue S22, also within the AKT recognition motif, were the most frequent. FOXO1 mutations were almost always present in the major tumor cell clone but were not associated with outcome. Analysis of other recurrent mutations reported in BL revealed that FOXO1 mutations were associated with mutations of DDX3X and ARID1A, but not MYC, TCF3/ID3, or members of the phosphatidylinositol 3-kinase signaling pathway. We further show common nuclear retention of the FOXO1 protein, irrespective of mutation status, suggesting alternative unknown mechanisms for maintaining FOXO1 transcriptional activity in BL. CRISPR/Cas9 knockout of FOXO1 in an endemic cell line produced a significant decrease in cell proliferation, supporting an oncogenic role for FOXO1 in endemic BL. Thus, FOXO1 is frequently mutated in both sporadic and endemic BL and may offer a potential therapeutic target for pediatric BL patients worldwide.
引用
- Zhou P, Blain AE, Newman AM, et al. Sporadic and endemic Burkitt lymphoma have frequent FOXO1 mutations but distinct hotspots in the AKT recognition motif. Blood Adv. 2019. PMID: 31300419. doi:10.1182/bloodadvances.2018029546
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。